Disc Medicine Inc. (IRON)
52.22
-0.25 (-0.48%)
At close: Mar 28, 2025, 2:25 PM
Company Description
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis.
The company is based in Watertown, Massachusetts.
Disc Medicine Inc.
| Country | United States |
| IPO Date | Aug 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 84 |
| CEO | Dr. John D. Quisel Esq., J.D., Ph.D. |
Contact Details
Address: 321 Arsenal Street Watertown, Massachusetts United States | |
| Website | https://www.discmedicine.com |
Stock Details
| Ticker Symbol | IRON |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001901203 |
| CUSIP Number | |
| ISIN Number | US2546041011 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Dr. John D. Quisel Esq., J.D., Ph.D. | Chief Executive Officer, President & Director |
| Jean M. Franchi CPA | Chief Financial Officer |
| Dr. Brian MacDonald ChB, MB, Ph.D. | Founder & Chair of Scientific Advisory Board |
| Dr. Donald William Nicholson Ph.D. | Executive Chairman |
| Dr. Rahul Khara J.D., Pharm.D. | General Counsel, Compliance Officer & Secretary |
| Dr. Rahul Rajan Kaushik Ph.D. | Chief Technical Officer |
| Dr. William Jacob Savage M.D., Ph.D. | Chief Medical Officer |
| Hua Yang Ph.D. | Senior Vice President & Head of Early Development and Clinical Pharmacology |
| Jonathan Yu M.B.A. | Chief Opearating Officer |
| Srikanth Venkatraman Ph.D. | Senior Vice President & Head of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | S-4/A | [Amend] Filing |
| Feb 25, 2025 | 4 | Filing |
| Feb 25, 2025 | 3 | Filing |
| Feb 21, 2025 | 10-K | Annual Report |
| Jan 31, 2025 | SCHEDULE 13G | Filing |
| Jan 28, 2025 | S-4/A | [Amend] Filing |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 19, 2024 | 425 | Filing |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 19, 2024 | S-4 | Filing |